ATE459625T1 - Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het - Google Patents

Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het

Info

Publication number
ATE459625T1
ATE459625T1 AT99929394T AT99929394T ATE459625T1 AT E459625 T1 ATE459625 T1 AT E459625T1 AT 99929394 T AT99929394 T AT 99929394T AT 99929394 T AT99929394 T AT 99929394T AT E459625 T1 ATE459625 T1 AT E459625T1
Authority
AT
Austria
Prior art keywords
het
protein
treatment
production
medicinal product
Prior art date
Application number
AT99929394T
Other languages
English (en)
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE459625T1 publication Critical patent/ATE459625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AT99929394T 1998-07-08 1999-07-05 Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het ATE459625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808731A FR2780974B1 (fr) 1998-07-08 1998-07-08 Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
PCT/FR1999/001609 WO2000002881A2 (fr) 1998-07-08 1999-07-05 Utilisation de derives de la cysteine pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimerique

Publications (1)

Publication Number Publication Date
ATE459625T1 true ATE459625T1 (de) 2010-03-15

Family

ID=9528405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929394T ATE459625T1 (de) 1998-07-08 1999-07-05 Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het

Country Status (17)

Country Link
US (3) US6544995B1 (de)
EP (1) EP1100801B1 (de)
JP (1) JP2002520327A (de)
AR (1) AR019908A1 (de)
AT (1) ATE459625T1 (de)
AU (1) AU756268B2 (de)
CA (1) CA2336846C (de)
DE (1) DE69942095D1 (de)
ES (1) ES2341404T3 (de)
FR (1) FR2780974B1 (de)
MY (1) MY122419A (de)
NO (1) NO319633B1 (de)
NZ (1) NZ509789A (de)
RU (1) RU2268889C2 (de)
TW (1) TW561156B (de)
WO (1) WO2000002881A2 (de)
ZA (1) ZA200101061B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US7084135B1 (en) 1998-12-31 2006-08-01 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Prenyl transferase inhibitors
EP1382607B1 (de) * 1998-12-31 2009-08-19 Ipsen Pharma Prenyl transferasinhibitoren
DE10112926B4 (de) * 2001-03-13 2005-11-10 Schebo Biotech Ag Verwendung von Aminooxyacetat zur Tumorbehandlung
DE10112925A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1583534A4 (de) * 2002-12-20 2007-08-29 Merck & Co Inc 3-amino-4-phenylbutansäure-derivate als dipeptidyl-peptidase-hemmer zur behandlung oder prävention von diabetes
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
FR2921658A1 (fr) * 2007-09-27 2009-04-03 Sod Conseils Rech Applic Derives des pyrazolo-pyrazines comme inhibiteurs de proteines g
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
TWI421252B (zh) 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA39849C2 (uk) * 1991-03-26 2001-07-16 Ф.Хоффманн-Ля Рош Аг ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ
ES2075630T3 (es) * 1991-10-11 1995-10-01 Squibb & Sons Inc Uso de inhibidores de la proteina-farnesil transferasa para la preparacion de un medicamento para bloquear la transformacion neoplastica de celulas inducidas por oncogenes ras.
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase
CA2165176A1 (en) * 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase
AU702075B2 (en) * 1994-04-26 1999-02-11 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
CA2159850A1 (en) * 1994-11-03 1996-05-04 Yadagiri Pendri Phosphonosulfonate squalene synthetase inhibitor salts and method
WO1996021456A1 (en) * 1995-01-12 1996-07-18 University Of Pittsburgh Inhibitors of prenyl transferases
FR2736638B1 (fr) * 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
US5935812A (en) * 1996-09-18 1999-08-10 Incyte Pharmaceuticals, Inc. Human GTP binding protein gamma-3
RU2201931C2 (ru) * 1996-11-20 2003-04-10 Биомежер Инкорпорэйтед Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique

Also Published As

Publication number Publication date
EP1100801B1 (de) 2010-03-03
FR2780974B1 (fr) 2001-09-28
RU2268889C2 (ru) 2006-01-27
US20030162786A1 (en) 2003-08-28
NO20010029L (no) 2001-01-08
JP2002520327A (ja) 2002-07-09
US6544995B1 (en) 2003-04-08
US20060035899A1 (en) 2006-02-16
TW561156B (en) 2003-11-11
WO2000002881A3 (fr) 2000-03-16
CA2336846A1 (en) 2000-01-20
EP1100801A2 (de) 2001-05-23
NO20010029D0 (no) 2001-01-03
US7034025B2 (en) 2006-04-25
NZ509789A (en) 2004-01-30
AR019908A1 (es) 2002-03-20
ZA200101061B (en) 2002-10-02
MY122419A (en) 2006-04-29
FR2780974A1 (fr) 2000-01-14
CA2336846C (en) 2010-03-16
ES2341404T3 (es) 2010-06-18
AU4622299A (en) 2000-02-01
WO2000002881A2 (fr) 2000-01-20
DE69942095D1 (de) 2010-04-15
AU756268B2 (en) 2003-01-09
NO319633B1 (no) 2005-09-05

Similar Documents

Publication Publication Date Title
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60043692D1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE69922930D1 (de) N-[(substitutierte fünfgliedrige di- oder triaza-doppeltungesättigter ring)carbonyl]guanidinderivate zur behandlung von ischemie
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
ATE459625T1 (de) Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
EP1584320A4 (de) Kosmetische zusammensetzung mit glycerylaminosäurederivaten
DE60127538D1 (de) Verfahren zur herstellung von methionin
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60108668D1 (de) Verfahren zur herstellung von phenethylamin-derivaten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60230464D1 (de) Verfahren und Form zur Herstellung von Tabletten aus heissschmelzbarer Tinte
DE69937692D1 (de) Arzneimittel zur behandlung der hemicrania
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties